



ECONOMIC EVALUATION IN HEALTH: COST-EFFECTIVENESS AND BEYOND

September 15-17, 2015

Harvard T.H. Chan School of Public Health
677 Huntington Avenue, Boston, MA, 02115
Building 1, Room 1208

Meeting Objectives

- (i) To provide background for a *DCP3* chapter on ECEA informed by broad economic perspectives and completed ECEAs, and addressing how ECEA should be adapted in the future (brief documents will be provided for all participants).
- (ii) To provide background for a *Priorities 2020* book chapter, with emphasis on normative issues in BCA.
- (iii) To inform (re-)calculation of the basic economics underlying *The Lancet* Commission on Investing in Health (Global Health 2035).
- (iv) To discuss future development of economic evaluation methods for health, most particularly methods for health policy analysis.

Meeting Agenda

Tuesday September 15, 2015

5:30pm: Reception, Squealing Pig, 134 Smith Street, Roxbury Crossing, MA 02120

Wednesday September 16, 2015

9:15-9:45am: Breakfast

9:45-10:00am: Welcome and introductions

10:00-12:00pm: **Session 1 - Background** (Chair: Lisa Robinson)

- Cost-effectiveness analysis at Harvard – Sue Goldie
- Beyond CEA and beyond GDP: current thinking about the economic consequences of disease and injury at WHO – Jeremy Lauer
- 2nd US Panel on Cost-Effectiveness in Health and Medicine and trends in published CEAs – Peter Neumann
- Priorities 2020 – Ole Frithjof Norheim
- Disease Control Priorities and the *Lancet* Commission on Investing in Health – Dean Jamison

12:00-1:00pm: Lunch

1:00-3:30pm: **Session 2 - Beyond cost-effectiveness analysis, examples** (Chair: Ole F. Norheim)

2.1 Extended cost-effectiveness analysis (ECEA)

- Public finance for tuberculosis treatment in India – Stéphane Verguet
- Alternative interventions in Ethiopia – Kjell Arne Johansson

Discussant – Milt Weinstein

2.2 Benefit-cost analysis (BCA)

- Non-health costs and benefits of WASH projects and how we account for these in economic evaluations – Claire Chase
- Valuation of change in mortality in the *Lancet* Commission on Investing in Health: A sensitivity analysis – Angela Chang

Discussant – Mark Shrimme

3:30-4:00pm: Break

4:00-5:30pm: **Session 3 - Issues in development of ECEA** (Chair: Ole F. Norheim)

- Measuring financial risk protection: catastrophic expenditures, impoverishments, money-metric value of insurance – Margaret Kruk
- Distributional concerns: income and health outcomes – Dean Jamison
- Policy instrument options – Stéphane Verguet

6:15pm: Drinks & Group Dinner, Bravo Restaurant, Museum of Fine Arts, 465 Huntington Avenue Boston, MA 02115

Thursday September 17, 2015

9:00-9:30am: Breakfast

9:30-11:00am: **Session 4 - Valuation of changes in health** (Chair: Stéphane Verguet)

- Where the literature stands on valuing change in mortality and morbidity – Lisa Robinson
- The value of a QALY – James Hammitt

Discussant – Jim Campen

11:00-11:30am: Coffee break

11:30-1pm: **Session 5 - Cost-effectiveness thresholds and the value of a year of life**

(Chair: Stéphane Verguet)

- CEA thresholds – Stephen Resch
- The use and misuse of GDP thresholds in priority setting: a WHO perspective – Jeremy Lauer

Discussant – Ole F. Norheim

1:00-2:00pm: Lunch

2:00-3:00pm: **Session 6 - Assessing the cost of diseases** (Chair: Dean Jamison)

- The example of malaria – Edith Patouillard
- The example of rheumatic heart disease – David Watkins
- Discussant – Josh Salomon

3:00-4:30pm: **Session 7 - Conclusions** (Chair: Dean Jamison)

- Reflections: Time to move beyond CEA?

Matt Adler

James Hammitt

Milt Weinstein

- Open Discussion with everyone